INOVIO, a biotechnology company focused on precisely designed DNA medicines, achieved positive safety, tolerability and immunogenicity data from its placebo-controlled and blinded Phase 2 segment of its Phase 2/3 clinical trial evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.   The Phase 2 segment of the trial enrolled approximately 400 partici...